Welcome to our dedicated page for OKYO Pharma SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
Mantelli Flavio reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd’s chief medical officer, Flavio Mantelli, received a grant of 20,000 shares of common stock on July 21, 2026. The award was recorded at $1.40 per share as direct ownership, and Mantelli now directly holds 20,000 shares of OKYO Pharma common stock.
OKYO Pharma Limited reported that Chairman Gabriele Cerrone, through Panetta Partners Ltd, acquired 22,500 ordinary shares at $1.45 per share. Following this purchase, he beneficially holds 10,873,916 ordinary shares, representing 20.55% of the company’s issued share capital.
OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases. The company plans a global Phase 3 pivotal trial of urcosimod in the second half of this year, targeting enrollment of approximately 111 patients on a single-dose regimen.
OKYO Pharma Limited reported that Chief Development Officer and Director Gary S. Jacob, PhD purchased 3,500 of the company’s ordinary shares on Nasdaq at $1.40 per share, increasing his total holdings to 112,420 ordinary shares.
The clinical-stage biopharmaceutical company develops therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases and plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share.
The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases and plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, reported a grant/award acquisition of 25,000 shares of common stock at $1.40 per share on July 20, 2026. Following this indirect transaction, his reported holdings via that entity are 10,851,416 shares.
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, announced that its CEO Robert J. Dempsey and CMO Flavio Mantelli will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 12:30 PM.
The company also plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain. OKYO states that this information is incorporated by reference into its Registration Statement on Form F-3 (Reg. No. 333-293145).
OKYO Pharma Limited reported that its Chairman, Gabriele Cerrone, through Panetta Partners Ltd, acquired 25,000 ordinary shares at $1.40 per share. Following this purchase, his total holding is 10,851,416 ordinary shares, representing 20.51% of the company’s issued share capital.
The company is a clinical-stage biopharmaceutical business focused on neuropathic corneal pain (NCP) and anterior segment eye diseases. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma Limited filed its Annual Report on Form 20‑F for the fiscal year ended March 31, 2026 and highlighted stronger funding for its lead eye‑disease program.
The company raised approximately $25 million during the year, including a February 2026 public offering of about $22 million in gross proceeds, and reported cash and cash equivalents of approximately $20.6 million as of the end of March 2026. Management states that this cash provides resources to be fully funded through completion of NEPTUNE, a global Phase 3 pivotal trial of urcosimod in neuropathic corneal pain.
NEPTUNE is planned to start in the second half of 2026, enrolling around 111 patients in the US and Europe, randomized 2:1 to receive 0.05% urcosimod or placebo in a single‑dose regimen, and is designed, with FDA Type D feedback, as a potential registrational study.
OKYO Pharma Limited, a Guernsey‑incorporated biotech listed on the Nasdaq Capital Market, reports on its fiscal year ended March 31, 2026 under IFRS, highlighting it remains a clinical‑stage company with no product revenue and a pipeline focused on ocular surface and corneal pain indications.
The lead candidate urcosimod (formerly OK‑101) is in mid‑stage development for neuropathic corneal pain and other anterior segment diseases, while OK‑201 is at an early stage. The company describes high clinical and regulatory failure risk, lengthy timelines and substantial uncertainty around ultimately achieving commercialization.
As of March 31, 2026, cash, cash equivalents and short‑term investments were $20.6 million, with a working capital surplus of $12.3 million, yet management expects significant ongoing losses and states it will need to raise substantial additional capital, potentially through dilutive equity or other financings, to fund research, trials, manufacturing arrangements and prospective commercialization. Extensive risk disclosures also cover dependence on third‑party manufacturers and CROs, intense competition in ocular disease, patent and trade‑secret challenges, pricing and reimbursement constraints, evolving US, UK and EU regulation (including GDPR), and potential product‑liability and cybersecurity exposures.
OKYO Pharma reports positive feedback from a U.S. FDA Type D meeting on its lead drug candidate, urcosimod, for neuropathic corneal pain (NCP). The agency aligned with a single-dose global Phase 3 pivotal trial, called NEPTUNE, and acknowledged a potential single-trial registration pathway, subject to successful results and continued review.
The NEPTUNE study is planned in the United States and Europe, enrolling about 111 patients in a 2:1 randomization of 0.05% urcosimod versus placebo. Urcosimod already has Fast Track designation, and OKYO plans to seek Breakthrough Therapy Designation to further accelerate development in this debilitating disease with no FDA-approved treatments.